| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-223 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-10 |
| filingDate |
1984-03-02^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1986-09-30^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d74dbb46dcf7f6148ae7756f4438010
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f41a12fd7db7832b602712193dea3216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_014cdf736fec57e262e24b7ba2675346 |
| publicationDate |
1986-09-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-4614793-A |
| titleOfInvention |
Hepatitis A--subunit antigen |
| abstract |
A surface structural protein of Hepatitis A Virus (HAV) has been isolated and characterized from virus grown in tissue culture. This 33,000 dalton viral protein (VP-1) reacts with immune HAV sera and monoclonal antibodies that neutralize HAV infectivity. The VP-1 is usable for the preparation of a polypeptide subunit vaccine for HAV. Hybridoma cells were made which produced monoclonal antibodies to HAV or VP-1. These monoclonal antibodies were found to neutralize the infectivity of HAV and to compete with polyclonal antibody derived from human HAV immune sera. The monoclonal antibodies are useful for the neutralization of infectious HAV, the detection of antibodies to neutralizing sites on HAV, and the diagnoses of HAV disease in humans and other susceptible hosts. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7282205-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03040341-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6136319-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004186089-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6194210-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9052304-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8906658-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004260067-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6299874-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8277651-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8277650-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8293100-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5871748-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8293101-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03040341-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5521082-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7635476-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5549896-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007287667-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5514376-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9304089-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5766603-A |
| priorityDate |
1983-10-14^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |